Dirk Demuth

667 total citations
42 papers, 453 citations indexed

About

Dirk Demuth is a scholar working on Epidemiology, Genetics and Immunology. According to data from OpenAlex, Dirk Demuth has authored 42 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 29 papers in Genetics and 15 papers in Immunology. Recurrent topics in Dirk Demuth's work include Inflammatory Bowel Disease (29 papers), Microscopic Colitis (24 papers) and Biosimilars and Bioanalytical Methods (13 papers). Dirk Demuth is often cited by papers focused on Inflammatory Bowel Disease (29 papers), Microscopic Colitis (24 papers) and Biosimilars and Bioanalytical Methods (13 papers). Dirk Demuth collaborates with scholars based in United States, United Kingdom and Canada. Dirk Demuth's co-authors include Laurent Peyrin‐Biroulet, Edward V. Loftus, Javaria Mona Khalid, Stefan Schreiber, Axel Dignaß, Mahmoud Mosli, Greg Hather, Andrés Yarur, Brian Bressler and Gerassimos J. Mantzaris and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Transplantation.

In The Last Decade

Dirk Demuth

41 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Demuth United States	9	320	279	113	78	70	42	453
Alexandra James United States	10	456 1.4×	409 1.5×	171 1.5×	130 1.7×	39 0.6×	20	634
Farhad Peerani Canada	8	344 1.1×	306 1.1×	166 1.5×	67 0.9×	16 0.2×	42	489
Steven Jeuring Netherlands	11	584 1.8×	465 1.7×	257 2.3×	61 0.8×	21 0.3×	27	679
María Dolores Martin‐Arranz Spain	13	384 1.2×	248 0.9×	254 2.2×	162 2.1×	12 0.2×	88	638
Nikolas Plevris United Kingdom	14	528 1.6×	423 1.5×	234 2.1×	177 2.3×	10 0.1×	53	699
Daniel Sjöberg Sweden	13	373 1.2×	371 1.3×	244 2.2×	42 0.5×	10 0.1×	25	605
Jacqueline Jossen United States	10	263 0.8×	204 0.7×	86 0.8×	115 1.5×	7 0.1×	13	358
J.‐F. Rahier Belgium	8	166 0.5×	160 0.6×	114 1.0×	190 2.4×	19 0.3×	14	446
Philippe Godeberge France	13	346 1.1×	297 1.1×	315 2.8×	71 0.9×	11 0.2×	25	687
K.H. Katsanos Greece	5	362 1.1×	296 1.1×	97 0.9×	153 2.0×	7 0.1×	14	501

Countries citing papers authored by Dirk Demuth

Since Specialization

Citations

This map shows the geographic impact of Dirk Demuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Demuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Demuth more than expected).

Fields of papers citing papers by Dirk Demuth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Demuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Demuth. The network helps show where Dirk Demuth may publish in the future.

Co-authorship network of co-authors of Dirk Demuth

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Demuth. A scholar is included among the top collaborators of Dirk Demuth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Demuth. Dirk Demuth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tedesco‐Silva, Hélio, et al.. (2023). Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review. Transplant Infectious Disease. 25(4). e14070–e14070. 5 indexed citations

Cho, Sung‐Yeon, Muhlis Cem Ar, Clarisse Martins Machado, et al.. (2023). Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: A systematic review. Transplant Infectious Disease. 25(4). e14083–e14083. 5 indexed citations

Shafie, Asrul Akmal, Edson Duarte Moreira, Alberta Di Pasquale, Dirk Demuth, & Joanne Yoong. (2023). Knowledge, Attitudes and Practices toward Dengue Fever, Vector Control, and Vaccine Acceptance Among the General Population in Countries from Latin America and Asia Pacific: A Cross-Sectional Study (GEMKAP). Vaccines. 11(3). 575–575. 21 indexed citations

Li, Ji, Zhanju Liu, P. Hu, et al.. (2022). Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterology. 22(1). 44–44. 12 indexed citations

Yamamoto‐Furusho, Jesús K., Alessandro Armuzzi, Webber Chan, et al.. (2020). Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. Digestive and Liver Disease. 52(8). 869–877. 16 indexed citations

Ooi, Choon Jin, Ida Hilmi, Hyo Jong Kim, et al.. (2020). Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intestinal Research. 19(1). 71–82. 16 indexed citations

Banerjee, Rupa, Sai Wei Chuah, Ida Hilmi, et al.. (2020). Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study. Intestinal Research. 19(1). 83–94. 15 indexed citations

Bressler, Brian, Andrés Yarur, Uri Kopylov, et al.. (2020). P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study. Journal of Crohn s and Colitis. 14(Supplement_1). S381–S382. 1 indexed citations

Dulai, Parambir S., Laurent Peyrin‐Biroulet, Kristen A. Hahn, et al.. (2019). P537 The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials. Journal of Crohn s and Colitis. 13(Supplement_1). S382–S383. 2 indexed citations

10.

Bressler, Brian, Gerassimos J. Mantzaris, Mark S. Silverberg, et al.. (2019). P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study. Journal of Crohn s and Colitis. 13(Supplement_1). S427–S428. 7 indexed citations

11.

Schreiber, Stefan, Axel Dignaß, Laurent Peyrin‐Biroulet, et al.. (2018). Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. Journal of Gastroenterology. 53(9). 1048–1064. 115 indexed citations

12.

Demuth, Dirk, Haridarshan Patel, & Shashi Adsul. (2018). Real World Treatment Persistence With Vedolizumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 113(Supplement). S370–S372. 2 indexed citations

13.

Schreiber, Stefan, Axel Dignaß, Laurent Peyrin‐Biroulet, et al.. (2017). P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis. Journal of Crohn s and Colitis. 11(suppl_1). S315–S315.

14.

Demuth, Dirk, et al.. (2016). Real-World Treatment Persistence with Vedolizumab in Crohnʼs Disease and Ulcerative Colitis Patients in the United States (US): A Retrospective Analysis Using the Optum Research Database. The American Journal of Gastroenterology. 111. S324–S324. 2 indexed citations

15.

Demuth, Dirk, et al.. (2015). A Description Of Real-World Treatment With Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer Patients In The Post-Chemotherapy Setting In France And The Netherlands. Value in Health. 18(7). A435–A435. 2 indexed citations

16.

Wahn, Ulrich, et al.. (2015). Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis. Allergy Asthma and Clinical Immunology. 11(1). 19–19. 8 indexed citations

17.

Kingswood, Christopher, Patrick Bolton, Pamela Crawford, et al.. (2015). The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: A retrospective cohort study in the Clinical Practice Research Datalink (CPRD). European Journal of Paediatric Neurology. 20(2). 296–308. 55 indexed citations

18.

Carroll, Stuart, et al.. (2012). PSY34 Understanding Disease Presentation and Patient-Reported and Economic Impact of Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN): Findings From the Zoster Quality of Life (ZQOL) Study. Value in Health. 15(7). A514–A514. 1 indexed citations

19.

FitzGerald, J. Mark, et al.. (2010). Pulmonary function testing in the Emergency Department and medications prescribed at discharge: results of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) study. Primary Care Respiratory Journal. 19(2). 155–162. 5 indexed citations

20.

Sieberhagen, Cyril, Ashley Brown, Dirk Demuth, James Livingstone, & Matthew Cramp. (2010). PTU-069 Predictors of hepatitis C treatment outcome in genotype 1 patients in a “real world” setting. A77.1–A77. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact